Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Mepolizumab effectiveness and identification of super-responders in severe asthma

Erin S. Harvey, David Langton, Constance Katelaris, Sean Stevens, Claude S. Farah, Andrew Gillman, John Harrington, Mark Hew, Vicky Kritikos, Naghmeh Radhakrishna, Philip Bardin, Matthew Peters, Paul N. Reynolds, John W. Upham, Melissa Baraket, Simon Bowler, Jeffrey Bowden, Jimmy Chien, Li Ping Chung, Christopher Grainge, Christine Jenkins, Gregory P. Katsoulotos, Joy Lee, Vanessa M. McDonald, Helen K. Reddel, Janet Rimmer, Peter A.B. Wark, Peter G. Gibson
European Respiratory Journal 2020 55: 1902420; DOI: 10.1183/13993003.02420-2019
Erin S. Harvey
1Centre of Excellence in Severe Asthma and Priority Research Centre for Healthy Lungs, Faculty of Health, University of Newcastle, Newcastle, Australia
2Dept of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Langton
3Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia
4Dept of Thoracic Medicine, Frankston Hospital, Frankston, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Constance Katelaris
5School of Medicine, Western Sydney University, Campbelltown, Australia
6Immunology and Allergy Unit, Campbelltown Hospital, Campbelltown, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sean Stevens
1Centre of Excellence in Severe Asthma and Priority Research Centre for Healthy Lungs, Faculty of Health, University of Newcastle, Newcastle, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claude S. Farah
7Dept of Thoracic Medicine, Concord Hospital, Concord, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Claude S. Farah
Andrew Gillman
8Allergy, Asthma and Clinical Immunology, Alfred Health, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Harrington
2Dept of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Hew
8Allergy, Asthma and Clinical Immunology, Alfred Health, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vicky Kritikos
9Dept of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naghmeh Radhakrishna
10Respiratory Dept, St Vincent's Hospital, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip Bardin
11Lung and Sleep Medicine, Monash University and Medical Centre, Clayton, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Peters
7Dept of Thoracic Medicine, Concord Hospital, Concord, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul N. Reynolds
12Lung Research, Hanson Institute and Dept of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John W. Upham
13Dept of Respiratory Medicine, Princess Alexandra Hospital, Woolloongabba, Australia
14The University of Queensland Diamantina Institute, Woolloongabba, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa Baraket
15South Western Sydney Clinical School, University of New South Wales, Sydney, Australia
16Ingham Institute for Applied Medical Research, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon Bowler
17Dept of Respiratory Medicine, Mater Hospital Brisbane, South Brisbane, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Bowden
18Respiratory and Sleep Services, Flinders Medical Centre and Flinders University, Bedford Park, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jimmy Chien
19Dept of Sleep and Respiratory Medicine, Westmead Hospital, Westmead, Australia
20School of Medicine, The University of Sydney, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Ping Chung
21Dept of Respiratory Medicine, Fiona Stanley Hospital, Murdoch, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Grainge
2Dept of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Jenkins
7Dept of Thoracic Medicine, Concord Hospital, Concord, Australia
22Concord Clinical School University of Sydney, Concord, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory P. Katsoulotos
23St George Specialist Centre, Kogarah, Australia
24St George and Sutherland Clinical School, University of New South Wales, Sydney, Australia
25Woolcock Institute of Medical Research, Glebe, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joy Lee
26Austin Health and Monash University, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vanessa M. McDonald
1Centre of Excellence in Severe Asthma and Priority Research Centre for Healthy Lungs, Faculty of Health, University of Newcastle, Newcastle, Australia
2Dept of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen K. Reddel
9Dept of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Helen K. Reddel
Janet Rimmer
25Woolcock Institute of Medical Research, Glebe, Australia
27St Vincent's Clinic, Darlinghurst, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter A.B. Wark
1Centre of Excellence in Severe Asthma and Priority Research Centre for Healthy Lungs, Faculty of Health, University of Newcastle, Newcastle, Australia
2Dept of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Peter A.B. Wark
Peter G. Gibson
1Centre of Excellence in Severe Asthma and Priority Research Centre for Healthy Lungs, Faculty of Health, University of Newcastle, Newcastle, Australia
2Dept of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: peter.gibson@health.nsw.gov.au
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Severe asthma is a high-burden disease. Real-world data on mepolizumab in patients with severe eosinophilic asthma is needed to assess whether the data from randomised controlled trials are applicable in a broader population.

The Australian Mepolizumab Registry (AMR) was established with an aim to assess the use, effectiveness and safety of mepolizumab for severe eosinophilic asthma in Australia.

Patients (n=309) with severe eosinophilic asthma (median age 60 years, 58% female) commenced mepolizumab. They had poor symptom control (median Asthma Control Questionnaire (ACQ)-5 score of 3.4), frequent exacerbations (median three courses of oral corticosteroids (OCS) in the previous 12 months), and 47% required daily OCS. Median baseline peripheral blood eosinophil level was 590 cells·µL−1. Comorbidities were common: allergic rhinitis 63%, gastro-oesophageal reflux disease 52%, obesity 46%, nasal polyps 34%.

Mepolizumab treatment reduced exacerbations requiring OCS compared with the previous year (annualised rate ratio 0.34 (95% CI 0.29–0.41); p<0.001) and hospitalisations (rate ratio 0.46 (95% CI 0.33–0.63); p<0.001). Treatment improved symptom control (median ACQ-5 reduced by 2.0 at 6 months), quality of life and lung function. Higher blood eosinophil levels (p=0.003) and later age of asthma onset (p=0.028) predicted a better ACQ-5 response to mepolizumab, whilst being male (p=0.031) or having body mass index ≥30 (p=0.043) predicted a lesser response. Super-responders (upper 25% of ACQ-5 responders, n=61, 24%) had a higher T2 disease burden and fewer comorbidities at baseline.

Mepolizumab therapy effectively reduces the significant and long-standing disease burden faced by patients with severe eosinophilic asthma in a real-world setting.

Abstract

In clinical practice, mepolizumab reduces the burden of severe eosinophilic asthma by reducing severe exacerbations and improving asthma control, quality of life and lung function. Super-responders have a T2 phenotype and few comorbidities. http://bit.ly/2UIio4x

Footnotes

  • This article has supplementary material available from erj.ersjournals.com

  • Author contributions: All authors were involved in data interpretation and critical review of the manuscript. P.G. Gibson, E.S. Harvey, D. Langton, C. Katelaris, C.S. Farah, A. Gillman, J. Harrington, M. Hew, V. Kritikos, N. Radhakrishna, P. Bardin, M. Peters, P.N. Reynolds and J.W. Upham contributed to development of study concept and design. S. Stevens performed data analysis. E.S. Harvey, P.G. Gibson, D. Langton, C. Katelaris, C.S. Farah, A. Gillman, J. Harrington, M. Hew, V. Kritikos and N. Radhakrishna drafted the manuscript.

  • Conflict of interest: E.S. Harvey reports grants from GlaxoSmithKline that were paid to her employer, during the conduct of the study.

  • Conflict of interest: D. Langton has received fees from GlaxoSmithKline for participation in severe asthma advisory boards.

  • Conflict of interest: C. Katelaris reports grants from GlaxoSmithKline, during the conduct of the study; grants and personal fees for advisory board work and lectures from Sanofi, Novartis and CSL, personal fees from Seqirus and Takeda, outside the submitted work.

  • Conflict of interest: S. Stevens has nothing to disclose.

  • Conflict of interest: C.S. Farah reports personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Sanofi Genzyme, outside the submitted work.

  • Conflict of interest: A. Gillman reports personal fees for advisory board work and education from GlaxoSmithKline, outside the submitted work.

  • Conflict of interest: J. Harrington reports personal fees for education and advisory board work from AstraZeneca and GlaxoSmithKline, personal fees for education from Novartis, outside the submitted work.

  • Conflict of interest: M. Hew reports grants and personal fees from AstraZeneca, GlaxoSmithKline and Novartis, personal fees from Sanofi, Teva and Seqirus, outside the submitted work; all paid to his institutional employer Alfred Health.

  • Conflict of interest: V. Kritikos has nothing to disclose.

  • Conflict of interest: N. Radhakrishna reports grants from Sanofi, outside the submitted work.

  • Conflict of interest: P. Bardin reports per patient trial participation fees from Monash Lung and Sleep, during the conduct of the study; personal fees for advisory board work from Philip Bardin, outside the submitted work.

  • Conflict of interest: M. Peters reports personal fees for advisory board work from Sanofi Genzyme, Novartis Pharmaceuticals and AstraZeneca, outside the submitted work.

  • Conflict of interest: P.N. Reynolds reports grants from GlaxoSmithKline and AstraZeneca, during the conduct of the study.

  • Conflict of interest: J.W. Upham reports grants and personal fees from AstraZeneca and GlaxoSmithKline, personal fees from Novartis and Boehringer Ingelheim, outside the submitted work.

  • Conflict of interest: M. Baraket has nothing to disclose.

  • Conflict of interest: S. Bowler reports personal fees for advisory board work from GlaxoSmithKline, outside the submitted work.

  • Conflict of interest: J. Bowden reports personal fees for advisory board work from GlaxoSmithKline, AstraZeneca and Novartis, outside the submitted work.

  • Conflict of interest: J. Chien reports personal fees from GlaxoSmithKline, outside the submitted work.

  • Conflict of interest: L.P. Chung has nothing to disclose.

  • Conflict of interest: C. Grainge reports personal fees from Boehringer Ingelheim, Roche Pharmaceuticals and GlaxoSmithKline, outside the submitted work.

  • Conflict of interest: C. Jenkins reports personal fees for advisory board work, conducting meetings and developing educational content, and non-financial support from AstraZeneca, personal fees for advisory board work from Boehringer Ingleheim, grants and personal fees for advisory board work from GlaxoSmithKline, personal fees for advisory board work, facilitating symposia and developing educational content from Novartis, outside the submitted work.

  • Conflict of interest: G.P. Katsoulotos has nothing to disclose.

  • Conflict of interest: J. Lee reports personal fees for lectures from Boehringer Ingelheim and AstraZeneca, personal fees for consultancy from GlaxoSmithKline, outside the submitted work.

  • Conflict of interest: V.M. McDonald reports grants and personal fees from GlaxoSmithKline, AstraZeneca and Menarini, outside the submitted work.

  • Conflict of interest: H.K. Reddel reports grants from GlaxoSmithKline, during the conduct of the study; grants and personal fees for data monitoring committee work, advisory board work, providing independent medical education and consultancy from AstraZeneca, grants, personal fees for data monitoring committee work, advisory board work, providing independent medical education and consultancy and non-financial support (study medication) from GlaxoSmithKline, personal fees for data monitoring committee work from Merck, grants and personal fees for data monitoring committee work, advisory board work and providing independent medical education from Novartis, personal fees for providing independent medical education from Teva and Mundipharma, personal fees for advisory board work and providing independent medical education from Boehringer Ingelheim, personal fees for advisory board work from Sanofi Genzyme, outside the submitted work.

  • Conflict of interest: J. Rimmer has nothing to disclose.

  • Conflict of interest: P.A.B. Wark has nothing to disclose.

  • Conflict of interest: P.G. Gibson reports grants from GlaxoSmithKline, during the conduct of the study; personal fees for lectures from AstraZeneca, GlaxoSmithKline and Novartis, grants from AstraZeneca and GlaxoSmithKline, outside the submitted work.

  • Support statement: The Australian Mepolizumab Registry is an investigator-initiated and managed study funded through the GlaxoSmithKline Investigator-Sponsored Studies program. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received December 17, 2019.
  • Accepted February 7, 2020.
  • Copyright ©ERS 2020
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 55 Issue 5 Table of Contents
European Respiratory Journal: 55 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Mepolizumab effectiveness and identification of super-responders in severe asthma
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Mepolizumab effectiveness and identification of super-responders in severe asthma
Erin S. Harvey, David Langton, Constance Katelaris, Sean Stevens, Claude S. Farah, Andrew Gillman, John Harrington, Mark Hew, Vicky Kritikos, Naghmeh Radhakrishna, Philip Bardin, Matthew Peters, Paul N. Reynolds, John W. Upham, Melissa Baraket, Simon Bowler, Jeffrey Bowden, Jimmy Chien, Li Ping Chung, Christopher Grainge, Christine Jenkins, Gregory P. Katsoulotos, Joy Lee, Vanessa M. McDonald, Helen K. Reddel, Janet Rimmer, Peter A.B. Wark, Peter G. Gibson
European Respiratory Journal May 2020, 55 (5) 1902420; DOI: 10.1183/13993003.02420-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Mepolizumab effectiveness and identification of super-responders in severe asthma
Erin S. Harvey, David Langton, Constance Katelaris, Sean Stevens, Claude S. Farah, Andrew Gillman, John Harrington, Mark Hew, Vicky Kritikos, Naghmeh Radhakrishna, Philip Bardin, Matthew Peters, Paul N. Reynolds, John W. Upham, Melissa Baraket, Simon Bowler, Jeffrey Bowden, Jimmy Chien, Li Ping Chung, Christopher Grainge, Christine Jenkins, Gregory P. Katsoulotos, Joy Lee, Vanessa M. McDonald, Helen K. Reddel, Janet Rimmer, Peter A.B. Wark, Peter G. Gibson
European Respiratory Journal May 2020, 55 (5) 1902420; DOI: 10.1183/13993003.02420-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Shareable PDF
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • Asthma medication in obese and healthy weight asthma
  • The impact of COVID-19 on patients with asthma
  • FEV1 decline and cardiovascular disease in COPD
Show more Original Articles

Asthma

  • Asthma medication in obese and healthy weight asthma
  • Cost-effectiveness of azithromycin in reducing asthma exacerbations
  • Complement C3 and allergic asthma
Show more Asthma

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society